Urinary bladder: normal appearance and mimics of malignancy at CT urography

Atul B. Shinagare, Cheryl A. Sadow, V. Anik Sahni and Stuart G. Silverman

Division of Abdominal Imaging and Intervention, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA

Corresponding address: Atul B. Shinagare, Division of Abdominal Imaging and Intervention, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115 USA.

Email: ashinagare@partners.org

Date accepted for publication 11 May 2011

Abstract

The objective of this review article is to learn how to recognize anatomic variants and benign entities that mimic bladder cancer at computed tomography (CT) urography. Building on recent data that suggest that CT urography can be used to diagnose bladder cancer, recognition of anatomic variants and benign entities will help improve radiologists’ ability to diagnose bladder cancer.

Keywords: Computed tomography; urography; bladder cancer; anatomic variants; pitfalls.

Introduction

With an estimated 70,530 new cases and 14,680 deaths in the United States in 2010, bladder cancer is the most common malignancy of the urothelium and kidneys[1]. Metachronous disease is common, and surveillance for additional tumors is a lifelong challenge in patients with bladder cancer[2].

CT urography (CTU) is defined as a CT examination of the urinary tract that is performed both before and after intravenous (IV) contrast material, and includes excretory phase images[3]. CTU is emerging as the imaging test of choice for the evaluation of the urothelium[3,4,10]. We obtain an unenhanced CT scan of the abdomen and pelvis to identify calculi, including those in the bladder, that could be masked by excreted contrast material. Unenhanced CT scans also allow measurement of the native attenuation of masses throughout the urinary tract that can be used to assess for enhancement. In patients over the age of 40 years, we image the kidneys in the nephrographic phase at 100 s after contrast material injection (80 ml of iodinated contrast material; 370 mg I/ml), to detect and characterize renal masses. An excretory phase scan of the abdomen and pelvis is obtained at 15 min[3,5,7,10,14]. In patients 40 years or younger, a split-bolus, two-phase protocol is used to limit radiation exposure. Following an unenhanced scan of the abdomen and pelvis, 40 ml of IV contrast medium are administered. After an 8-min delay, 80 ml of IV contrast medium are administered and followed by a scan of the abdomen and pelvis at 100 s. Both protocols may be augmented with 250 ml of IV normal saline infused during the delay periods[3,5,7,10,14]. We prefer to administer 10 mg of IV furosemide (Lasix; Abbott Laboratories, North Chicago, IL) 2–3 min before the intravenous contrast material in patients over the age of 40 years. Furosemide, and to some extent saline, contribute to
distension of the upper urinary tracts and bladder during excretory phase imaging.

An underdistended bladder can appear thickened, particularly along its anterior wall, and mimic bladder cancer (Fig. 1). Since the specific gravity of contrast medium is higher than urine, incomplete mixing of unopacified urine and contrast material often results in a urine contrast level. Furosemide increases urinary flow rate, thereby increasing both distention and mixing of the contrast material, the latter likely via an increased ureteral jet phenomenon[11]. Others have used a log-rolling technique to promote mixing of contrast material and urine in the bladder[3]. Wide window settings may be required, particularly if CTU is not supplemented with furosemide, as dense contrast material may obscure small urothelial masses[12] (Fig. 2).

**Normal anatomy**

The distended bladder has a round or oval form with a peritoneum-covered dome. The remaining surfaces of the bladder abut the extraperitoneal space. The apex of the bladder, connected to the umbilicus by the urachus during embryologic development, is directed anterosuperiorly; the bladder neck is positioned inferiorly. A prominent urachal remnant may cause focal nodularity at the anterosuperior aspect of the bladder and mimic a mass (Fig. 3). This pitfall may be avoided by noting that the
thickening is limited to the serosal side of the bladder, midline, and is contiguous with the fibrous urachal remnant (the median umbilical ligament) extending anterosuperiorly towards the umbilicus.

The internal urethral orifice is located at the bladder neck at the inferior angle of the trigone. The ureters traverse a short, oblique, intramuscular course before opening at the posterolateral angles of the trigone at the ureterovesical junction (UVJ). The intramural ureter may appear to protrude into the bladder lumen, and can simulate a bladder mass depending on the location of the UVJ, the angle at which the ureter inserts, and the imaging plane (Fig. 4). A tumor can often be excluded by noting that the bulge is subtle, located at the UVJ, and bilateral, with symmetry in at least one imaging plane. In contradistinction, cancers at the UVJ (Fig. 5) typically cause more mass effect. However, benign processes such as post-operative changes

Figure 3  (a) A 31-year-old woman with hematuria and a prominent urachal remnant. Axial image from the excretory phase of a CT urogram demonstrates focal thickening of the anterior bladder wall in the midline (arrow). Physiologic changes are seen in the left ovary (arrowhead). (b) Sagittal image from the excretory phase of a CT urogram demonstrates thickening limited to the serosal surface of the bladder wall (arrow). Also note a thin linear remnant extends from the bladder dome to the umbilicus (arrowheads). The urine analysis was normal 2 years after the examination, and no cause for the patient’s hematuria was found.

Figure 4  (a) An 84-year-old man with a history of bladder cancer and normal CT urogram. Axial image from the excretory phase of a CT urogram shows apparent thickening of a normal left ureterovesical junction (UVJ) (arrow). (b) Coronal reformations demonstrate normal symmetric appearance of the bilateral ureterovesical junctions (arrows). Note the enlarged prostate gland (curved arrow).
(Fig. 6) and endometriosis (Fig. 7) can be mass-like and mimic cancer.

**Inflammatory processes**

Several inflammatory and infectious processes, such as hemorrhagic cystitis (Fig. 8), schistosomiasis, tuberculosis, and radiation-induced cystitis generally cause diffuse, symmetric bladder wall thickening\(^\text{[13]}\). Bladder cancer only rarely causes diffuse symmetric bladder wall thickening\(^\text{[14]}\). Diffuse or multifocal bladder cancer typically causes asymmetric, multifocal wall thickening (Fig. 9). Rarely, inflammatory conditions such as cystitis glandularis (Fig. 10) and endometriosis (Fig. 7) can cause focal bladder wall thickening and mimic cancer. Calcifications not associated with a mass or focal thickening (Fig. 11), and those associated with diffuse wall thickening are likely benign. However, urothelial carcinoma may calcify (Fig. 12), and therefore cancer should be suspected when calcification is associated with a mass.

**Treatment effects**

In patients with a history of bladder cancer, prior surgical treatment may cause focal wall thickening and abnormal enhancement that may be indistinguishable from recurrent tumor, even at cystoscopy\(^\text{[14]}\) (Figs. 6, 13, 14).
A 53-year-old man with gross hematuria and urothelial carcinoma. Coronal image from the excretory phase of a CT urogram demonstrates multifocal nodular wall thickening (arrows) involving most of the bladder, and causing bilateral hydronephrosis and hydroureter (arrowheads). Cystoscopic biopsy revealed urothelial carcinoma. Surgical pathology at cystectomy revealed multifocal high grade urothelial carcinoma.

A 55-year-old man with gross hematuria. Coronal image from the excretory phase of a CT urogram shows diffuse bladder wall thickening with irregularity of the urothelial surface (arrowheads). Cystoscopy revealed severe hemorrhagic cystitis. The left ureter (curved arrow) is mildly obstructed due to the thickened wall.

A 75-year-old man with hematuria. Axial image from the excretory phase of a CT urogram shows focal thickening of the posterior bladder wall (arrow), and an enlarged left external iliac lymph node (arrowhead). Cystoscopic biopsy revealed cystitis glandularis.

A 75-year-old woman with a history of bladder cancer treated with intravesical Bacillus Calmette-Guérin (BCG). Axial image from the excretory phase of a CT urogram demonstrates foci of bladder wall calcification (arrows) without associated mass or wall thickening. Multiple other similar foci were present. Biopsy revealed chronic inflammation and granulomas at all sites, related to prior BCG treatment.
Patients who have received intravesical immunotherapy with Bacillus Calmette-Guérin (BCG) may develop granulomatous changes in the bladder wall, mimicking bladder cancer [15] (Fig. 12). As above, radiation therapy can cause diffuse bladder wall thickening due to cystitis. Knowledge of past history and the presence of radiation-induced changes in nearby small bowel loops can help reach the diagnosis.

Blood clot

Blood clots can simulate bladder neoplasms, however, they are typically odd-shaped or linear, smoothly margined; they do not enhance. Also, they are luminal findings, and multiplanar reformations can be used to demonstrate that they do not arise from the bladder mucosa (Fig. 15). Cystoscopy may be needed to distinguish clots that abut or adhere to the bladder wall, from urothelial cancer (Fig. 16).

Enlarged prostate gland

Benign prostatic hyperplasia (BPH) can cause bladder outlet obstruction and bladder wall thickening due to detrusor muscle hypertrophy (Fig. 17). Both BPH (Fig. 18) and prostate cancer (Fig. 19) can cause protrusion of nodular, mass-like tissue into the bladder at its
Figure 15  (a) A 74-year-old man with hematuria. Axial image from the excretory phase of a CT urogram shows irregular soft tissue at the bladder base, projecting into the bladder lumen (arrows). (b) Coronal reformations demonstrate linear structures in the bladder lumen without attachment to the bladder mucosa (arrows). Also note nodular enlarged prostate gland indenting the bladder base (curved arrow). Cystoscopy demonstrated blood clots without bladder cancer.

Figure 16  A 77-year-old man with hematuria. Axial image from the excretory phase of a CT urogram shows an apparent papillary mass at the bladder base (arrow), concerning for bladder cancer. Cystoscopy revealed a blood clot adherent to the bladder wall, without evidence of bladder cancer.

Figure 17  An 83-year-old man with a prolonged history of urinary frequency, urgency and dysuria secondary to benign prostatic hyperplasia. Severe diffuse symmetric bladder wall thickening (arrows) due to detrusor muscle hypertrophy is mildly obstructive, manifested as mild left hydroureteronephrosis (arrowheads) and mild right hydroureter (curved arrow).
This nodular tissue may be asymmetric, and can have either a smooth or an irregular surface. Distinguishing a bladder base cancer from an enlarged prostate gland therefore may be difficult with excretory phase imaging, even using coronal reformations\(^{14}\) (Fig. 20). Since urothelial cancers are typically hypervascular, bladder base urothelial cancers can be differentiated from the prostate gland when the pelvis is examined 70 s after the injection of IV contrast material, when the bladder is distended with unopacified urine\(^{18,9}\). However, addition of these images to the CTU protocol described above would increase the radiation dose of the examination.

CTU is emerging as a method that can be used to diagnose bladder cancer\(^ {6-9}\). Knowledge of normal anatomy and benign conditions that mimic neoplastic disease will help reduce the number of false-positive CT urograms. Although cystoscopy will be needed to differentiate benign from malignant bladder processes in some situations, continued experience with CTU and

---

**Figure 18** A 76-year-old man with urinary frequency, urgency and dysuria. Axial image from the excretory phase of a CT urogram shows papillary-appearing soft tissue at the bladder base (arrows). Cystoscopy revealed benign prostatic hyperplasia with prostatic tissue protruding into the bladder lumen.

**Figure 19** An 87-year-old man with urinary frequency, urgency, and dysuria. Coronal image from the excretory phase of a CT urogram shows a smooth nodular soft tissue mass contiguous with prostate, projecting into the bladder base (arrow) to the left of a urinary catheter (curved arrow). Histopathology revealed prostate cancer.

**Figure 20** An 81-year-old man with urinary frequency, urgency and dysuria. Coronal image from the excretory phase of a CT urogram shows an apparent mass (arrows) at the bladder base inseparable from the prostate gland. Cystoscopic biopsy revealed a urothelial carcinoma at the bladder base.
knowledge of the appearance of benign conditions will help limit the number of patients needing further investigation.

References

[1] Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277–300. doi:10.3322/caac.20073.

[2] Donat SM. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am 2003; 30: 765–76. doi:10.1016/S0094-0143(03)00060-0.

[3] Washburn ZW, Dillman JR, Cohan RH, Caoli EM, Ellis JH. Computed tomographic urography update: an evolving urinary tract imaging modality. Semin Ultrasound CT MR 2009; 30: 233–45. doi:10.1053/j.sult.2009.03.005.

[4] Silverman SG, Leyendecker JR, Amis ES. What is the current role of CT urography and MR urography in the evaluation of the urinary tract? Radiology 2009; 250: 309–23. doi:10.1148/radiol.2502080534.

[5] Choyke PL. Radiologic evaluation of hematuria: guidelines from the American College of Radiology’s appropriateness criteria. Am Fam Physician 2008; 78: 347–52.

[6] Sadow CA, Silverman SG, O’Leary MP, Signorovitch JE. Bladder cancer detection with CT urography in an Academic Medical Center. Radiology 2008; 249: 195–202. doi:10.1148/radiol.2491071860.

[7] Turney BW, Willatt JMG, Nixon D, Crew JP, Cowan NC. Computed tomographic urography for diagnosing bladder cancer. BJU Int 2006; 98: 345–8. doi:10.1111/j.1464-410X.2006.06216.x.

[8] Park SB, Kim JK, Lee HJ, Choi HJ, Cho K. Hematuria: portal venous phase multi detector row CT of the bladder—a prospective study. Radiology 2007; 245: 798–805. doi:10.1148/radiol.2452061060.

[9] Jinzaki M, Tanimoto A, Shinmoto H, et al. Detection of bladder tumors with dynamic contrast-enhanced MDCT. AJR Am J Roentgenol 2007; 188: 913–18. doi:10.2214/AJR.06.0511.

[10] McTavish JD, Jinzaki M, Zou KH, Nawfel RD, Silverman SG. Multi-detector row CT urography: comparison of strategies for depicting the normal urinary collecting system. Radiology 2002; 225: 783–90. doi:10.1148/radiol.2253011515.

[11] Silverman SG, Akbar SA, Mortele KJ, Tuncali K, Bhagwat JG, Seffter JL. Multi-detector row CT urography of normal urinary collecting system: furosemide versus saline as adjunct to contrast medium. Radiology 2006; 240: 749–55. doi:10.1148/rad.2403050233.

[12] Caoli EM, Cohani RH, Inampudi P, et al. MDCT urography of upper tract urothelial neoplasms. AJR Am J Roentgenol 2005; 184: 1873–81.

[13] Maher MM, Kalra MK, Rizzo S, Mueller PR, Saini S. Multidetector CT urography in imaging of the urinary tract in patients with hematuria. Korean J Radiol 2004; 5: 1–10. doi:10.3348/kjr.2004.5.1.1.

[14] Cohani RH, Caoli EM, Cowan NC, Weizer AZ, Ellis JH. MDCT Urography: exploring a new paradigm for imaging of bladder cancer. AJR Am J Roentgenol 2009; 192: 1501–8. doi:10.2214/AJR.09.0344.

[15] Ma W, Kang SK, Hricak H, Gerst SR, Zhang J. Imaging appearance of granulomatous disease after intravesical Bacille Calmette-Guerin (BCG) treatment of bladder carcinoma. AJR Am J Roentgenol 2009; 192: 1494–500. doi:10.2214/AJR.08.1962.

[16] Lieber MM, Jacobson DJ, McGree ME, St Sauver JL, Girman CJ, Jacobsen SJ. Intravesical prostatic protrusion in men in Olmsted County, Minnesota. J Urol 2009; 182: 2819–24. doi:10.1016/j.juro.2009.08.086.